Brian Ward

(MD McGill, MSc Oxford, FRCP (C))
Associate member

Centre for the Study of Host Resistance
Montreal General Hospital,
1650 Cedar Avenue
Montreal, Quebec H3G 1A4

Tel: (514)934-1934 ex 42810
Fax: (514)934-8347
[ MailTo('Email', 'brian.ward [at] mcgill.ca', 1); ]

Research Interests: The laboratory has three major areas of interest in international health: 1) Vaccines from concept to community: projects include the development of novel vaccines for nasal administration (eg: Toxoplasma gondii, Leishmania donovani, measles), animal models for vaccine responses and to Phase I-IV clinical studies including investigations of vaccine-associated adverse events 2) Development of novel treatments and new diagnostic tests for parasitic diseases with a particular focus on protozoan parasites that can be transmitted by transfusion (e: Chagas Disease, malaria, Leishmania, African sleeping sickness) and 3) Studies of HIV transmission in Africa including micronutrient interventions (eg: vitamin A, iron) as well as genetic and behavioural factors (eg: genes expressed in the placenta, breast feeding practices).

Publications

1. Ndao M, Nath-Chowdhury M, McKerrow J, Ward BJ. The novel protease inhibitor, K777, is effective against Cryptosporidum parvum in vitro and in vivo. (J Clin Invest resubmitted with revisions)
2. Roussy V, Serhir B, Ward BJ, Ndao M. Five year quality assurance program for commercial parasite serologies at the Canadian National Reference Center for Parasitology (NRCP). (J Clin Microbiol - submitted)
3. Berrizbeittia M, Ndao M, Bubis J, Gottschalk M, Ache A, Lacouture S, Medina M, Ward BJ. Validation of an enzyme immunoassay (EIA) for Chagas Disease using different antigens of Trypanosoma cruzi: Comparison between fixed-epimastigote, fixed-trypomastigote and trypomastigote secreted-excreted antigens (TESA) in blood banks in Venezuela. Transfusion 2006 (in press)
4. Berrizbeittia M, Ndao M, Ache A, Gottschalk M, Ward BJ. Development and evaluation of second generation enzyme immunoassay for Chagas disease based upon the TESA antigens of the trypomastigote form. J Clin Microbiol 2006 (in press)
5. Miranda-Verastegui C, Arevalo I, Llanos-Cuentas A, Ward BJ, Matlashewaski G.(2005) Randomized, double blind clinical trial of topical 5% imiquimod (Aldara™) with parenteral meglumine antimonate (Glucantime™) in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis 40(10):1395-403.
6. MacLean JD, Kokoskin E, Ward BJ, Gyorkos TW.(2004) Twenty years of malaria surveillance: missed epidemics and opportunities. Emerg Infect Dis 2004;10:1195-201
7. Ndao M, Bandyayera E, Kokoskin E, Gyorkos TW, MacLean JD, Ward BJ.(2004) Comparison of blood smear, antigen detection, and nested-PCR methods for screening refugees from regions where malaria is endemic after a malaria outbreak in Quebec, Canada.J Clin Microbiol. 42:2694-700
8. Berrizbietia M, Ndao M, Gottschalk M, Ache A, Vasquez F, Lacouture S, Medina M, Ward BJ.(2004) Development and comparison of enzyme immunoassays for diagnosis of Chagas' disease using fixed forms of Trypanosoma cruzi (Epimastigotes, Amastigotes, and Trypomastigotes) and assessment of antigen stability for the three assays. J Clin Microbiol. 42:1766-9

Keywords

Infectious diseases, international health, vaccine immunology, vaccine adverse events, diagnostic parasitology, clinical parasitology